Objectives
It was hypothesized that perfusion computed tomography (CT) blood flow (BF),
blood volume (BV) and vascular permeability surface-area (PS) product parameters would
be predictive of therapeutic anti-cancer agent uptake in pancreatic cancer, facilitating
image-guided interpretation of human treatments. The hypothesis was tested in an
orthotopic rabbit model of pancreatic cancer, by establishing the model, imaging with
endoscopic ultrasound and contrast CT, and spatially comparing the perfusion maps to the
ex vivo uptake values of injected photosensitizer, vertepofin.
Materials and Methods
Nine New Zealand White rabbits underwent direct pancreas implantation of VX2
tumors and CT perfusion or endoscopic ultrasound was performed 10 days
post-implantation. Verteporfin was injected during CT imaging and tissue was removed 1 h
post-injection for frozen tissue fluorescence scanning. Region-of-interest comparisons
of CT data with ex vivo fluorescence and histopathological staining
were performed.
Results
DCE-CT showed enhanced BF, BV, and PS in the tumor rim, and decreased BF, BV
and PS in the tumor core. Significant correlations were found between ex
vivo verteporfin concentration and each of BF, BV, and PS.
Conclusions
The efficacy of verteporfin delivery in tumors is estimated by perfusion CT,
providing a non-invasive method of mapping photosensitizer dose.